The agency will now require drug companies making GLP-1 receptor agonist therapies to add safety labels warning that they could cause non-arteritic anterior ischemic optic neuropathy, or NAION.


The agency will now require drug companies making GLP-1 receptor agonist therapies to add safety labels warning that they could cause non-arteritic anterior ischemic optic neuropathy, or NAION.